Nanobiotix Sa ADR (NBTX) has released an update.
Nanobiotix has reached a pivotal milestone by completing the Phase 1 dose escalation study of NBTXR3, a promising radioenhancer for the treatment of inoperable and recurrent non-small cell lung cancer (NSCLC). The study, performed in collaboration with The University of Texas MD Anderson Cancer Center, successfully identified a recommended dose for Phase 2 trials and demonstrated NBTXR3’s ease of injection and a favorable safety profile. The ongoing expansion part of the study aims to further assess the treatment’s safety and early signs of its effectiveness.
For further insights into NBTX stock, check out TipRanks’ Stock Analysis page.
